Skip to main content
See every side of every news story
Published • loading... • Updated

Axsome: Q3 Earnings Snapshot – WTOP News

Revenue rose 52% as AUVELITY gained traction and Axsome said commercial momentum accelerated across its product portfolio.

  • Axsome Therapeutics reported strong Q3 2026 results, with revenue accelerating behind AUVELITY's expansion into Alzheimer's disease agitation and depression, pushing the company to a $1 billion annualized revenue run-rate.
  • Primary care adoption drove this expansion, as the total number of prescribers reached 77,000. With primary care now representing 40% of the base and 25% of prescriptions, the drug successfully reaches broader markets beyond specialists.
  • Reported financial results included a narrowed net loss of $12.9 million. The quarter also saw $26.4 million in stock-based compensation expenses, reflecting the firm's ongoing investment in talent and commercial operations.
  • Payer coverage remained robust at approximately 89% of total lives. This extensive network ensures broad access for patients across key depression and agitation indications, supporting the company's long-term commercial goals and patient reach.
  • By May 1, 2027, the FDA is expected to reach a decision on AXS-12. The firm projects the treatment will eventually reach at least $8 billion in peak annual revenue across its approved indications.
Insights by Ground AI

162 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 49% of the sources are Center
49% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

asiae.co.kr broke the news on Monday, November 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal